We are pleased to announce that Sarepta's Phase 2 MOMENTUM trial is now recruiting in the UK at Alder Hey Children's NHS Foundation Trust.
This phase 2 study is designed to determine the maximum dose for Sarepta Therapeutics Exon 51 skipping therapy, as well as its safety and tolerability.
There will be two arms to the study - in Part A, patients will receive 1 of 5 doses of SRP-5051 monthly by intravenous infusion. Once the maximum dose has be has been determined, all patients will then roll over into Part B and will receive the maximum dose by intravenous infusion for 24 weeks. In Part B, an additional 15 patients will also be enrolled at the beginning of the study.
The trial is now recruiting in the UK at Alder Hey Children's NHS Foundation Trust.
The UK sites have not yet been finalised, we will provide an update once we have these detail
To receive clinical trial updates directly into your inbox, Join the Hub.